Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Basit Öğe Kaydı
dc.contributor.authorGurbuz, Mustafa
dc.contributor.authorKutlu, Yasin
dc.contributor.authorAkkus, Erman
dc.contributor.authorKoksoy, Elif Berna
dc.contributor.authorKose, Naziyet
dc.contributor.authorOven, Bala Basak
dc.contributor.authorUluc, Basak Oyan
dc.date.accessioned2024-02-23T13:43:51Z
dc.date.available2024-02-23T13:43:51Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractPurpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.en_US
dc.identifier.doi10.1007/s00432-022-04087-x
dc.identifier.endpage3555en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue12en_US
dc.identifier.pmid35689097en_US
dc.identifier.scopus2-s2.0-85131510571en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3547en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-022-04087-x
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10948
dc.identifier.volume148en_US
dc.identifier.wosWOS:000809330900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Cancer Research And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtezolizumaben_US
dc.subjectSmall Cell Lung Canceren_US
dc.subjectImmunotherapyen_US
dc.subjectPd-L1en_US
dc.titleAtezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu